Related Experiment Video
Updated: Nov 23, 2025
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
Basal Serum Thyroxine Level should Guide Initial Thyroxine Replacement Dose in Neonates with Congenital
Ceren Günbey1, Alev Özön2, E Nazlı Gönç2
1Hacettepe University Faculty of Medicine, Department of Pediatric Neurology, Ankara, Turkey
Insights
High-dose sodium levothyroxine (Na-LT4) for congenital hypothyroidism (CH) can cause hyperthyroidism. This study suggests adjusting initial Na-LT4 doses based on CH severity to minimize risks and optimize treatment.
Area of Science:
- Pediatric Endocrinology
- Thyroid Disorders
- Pharmacology
Background:
- Congenital hypothyroidism (CH) requires thyroid hormone replacement therapy.
- Current guidelines recommend high-dose sodium levothyroxine (Na-LT4) initiation (10-15 μg/kg/day).
- High initial doses of Na-LT4 may lead to iatrogenic hyperthyroidism.
Purpose of the Study:
- To evaluate the impact of varying initial Na-LT4 doses on serum thyroid hormone levels in CH patients.
- To determine if initial Na-LT4 dosage can be tailored based on CH severity.
- To assess the incidence of hyperthyroxinemia with different initial treatment regimens.
Main Methods:
- Retrospective analysis of 52 patients with primary CH.
- Classification of CH severity into mild, moderate, and severe based on initial free thyroxine (fT4) levels.
- Comparison of time to achieve target hormone levels and incidence of hyperthyroxinemia across severity groups.
Main Results:
- Initial mean Na-LT4 doses varied by severity: 6.9±3.3 μg/kg/day (mild), 9.4±2.2 μg/kg/day (moderate), and 10.2±2 μg/kg/day (severe).
- Time to reach target fT4 levels did not significantly differ by CH severity (p=0.478).
- Hyperthyroxinemia (fT4 >1.94 ng/dL) occurred in 25.9% (mild), 72.7% (moderate), and 57.1% (severe) of patients (p=0.016).
Conclusions:
- Not all CH patients necessitate high initial Na-LT4 doses; dosage may be guided by baseline thyroid hormone levels.
- Moderate and severe CH patients experienced iatrogenic hyperthyroxinemia even with doses near the lower recommended range.
- Lower initial Na-LT4 doses with closer early follow-up may be a safer approach for CH management.
Objective:
Initial high-dose sodium levothyroxine (Na-LT4) (10-15 μg/kg/day) replacement for primary congenital hypothyroidism (CH) is recommended in guidelines. However, high-dose Na-LT4 risks iatrogenic hyperthyroidism. The aim of this study was to investigate the normalizing effect of varying initial doses of Na-LT4 on serum thyroid hormone levels.
Methods:
Fifty-two patients were analyzed retrospectively. The patients were classified into mild (27/51.9%), moderate (11/21.1%) and severe (14/26.9%) CH, based on initial free thyroxine (fT4) levels. Time taken to achieve target hormone levels was compared within groups.
Results:
Initial mean Na-LT4 doses for mild, moderate and severe disease were 6.9±3.3, 9.4±2.2 and 10.2±2 μg/kg/day. Serum fT4 levels reached the upper half of normal range (>1.32 ng/dL) in a median of 16, 13 and 16 days in patients with mild, moderate and severe CH with the mean time from initial treatment to first control visit of 14.8±6 days (range 1-36). There was no significant difference in terms of time to achieve target fT4 hormone levels according to disease severity (p=0.478). Seven (25.9%), eight (72.7%) and eight (57.1%) patients experienced hyperthyroxinemia (serum fT4 >1.94 ng/dL) in the mild, moderate, and severe CH groups at the first visit, respectively (p=0.016).
Conclusion:
Not all patients diagnosed with CH require high-dose Na-LT4. Initial dose of Na-LT4 may be selected on the basis of pre-treatment thyroid hormone levels. Some patients with moderate and severe CH, experienced iatrogenic hyperthyroxinemia even though the dose was close to the lower limit of the recommended range in guidelines. We suggest that lower initial doses may be appropriate with closer follow-up within the first week.
Related Concept Videos
01:20Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
01:29Drug Dosing: Infants and Children
01:18Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion